TY - CHAP
T1 - Update on immunotherapy in AML and MDS
T2 - Monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice
AU - Masarova, Lucia
AU - Kantarjian, Hagop
AU - Ravandi, Farhad
AU - Sharma, Padmanee
AU - Garcia-Manero, Guillermo
AU - Daver, Naval
N1 - Publisher Copyright:
© Springer Nature Switzerland AG 2018.
PY - 2018
Y1 - 2018
N2 - In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical trials are currently ongoing in patients with AML and MDS, both in the frontline and relapsed refractory setting. Given the natural diversity of AML blasts, it became apparent that the best responses would be achieved with rationally designed combination strategies of immune therapy, molecular therapy, and chemotherapy. A number of such combinations are enrolling patients with AML in various clinical settings. Biomarkers to select the optimal combination regimen for individual patients are critical.
AB - In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical trials are currently ongoing in patients with AML and MDS, both in the frontline and relapsed refractory setting. Given the natural diversity of AML blasts, it became apparent that the best responses would be achieved with rationally designed combination strategies of immune therapy, molecular therapy, and chemotherapy. A number of such combinations are enrolling patients with AML in various clinical settings. Biomarkers to select the optimal combination regimen for individual patients are critical.
KW - Acute myeloid leukemia
KW - Immune checkpoint blockade
KW - Immunotherapy
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85058609905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058609905&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-02505-2_4
DO - 10.1007/978-3-030-02505-2_4
M3 - Chapter
C2 - 30539507
AN - SCOPUS:85058609905
T3 - Advances in Experimental Medicine and Biology
SP - 97
EP - 116
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -